BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34387004)

  • 1. Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.
    Gatti M; Rinaldi M; Ferraro G; Toschi A; Caroccia N; Arbizzani F; Raschi E; Poluzzi E; Pea F; Viale P; Giannella M
    Mycoses; 2021 Nov; 64(11):1317-1327. PubMed ID: 34387004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
    Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
    Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study.
    Rinaldi M; Bartoletti M; Ferrarese A; Franceschini E; Campoli C; Coladonato S; Pascale R; Tedeschi S; Gatti M; Cricca M; Ambretti S; Siniscalchi A; Morelli MC; Cescon M; Cillo U; Di Benedetto F; Burra P; Mussini C; Cristini F; Lewis R; Viale P; Giannella M
    Transpl Infect Dis; 2021 Aug; 23(4):e13608. PubMed ID: 33768656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.
    Winston DJ; Limaye AP; Pelletier S; Safdar N; Morris MI; Meneses K; Busuttil RW; Singh N
    Am J Transplant; 2014 Dec; 14(12):2758-64. PubMed ID: 25376267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
    Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
    BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anti-fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta-analysis.
    Liu Y; Lan C; Qin S; Qin Z; Zhang Z; Zhang P; Cao W
    Mycoses; 2022 Oct; 65(10):906-917. PubMed ID: 35899464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
    Playford EG; Webster AC; Sorell TC; Craig JC
    Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
    Saliba F; Pascher A; Cointault O; Laterre PF; Cervera C; De Waele JJ; Cillo U; Langer RM; Lugano M; Göran-Ericzon B; Phillips S; Tweddle L; Karas A; Brown M; Fischer L; ;
    Clin Infect Dis; 2015 Apr; 60(7):997-1006. PubMed ID: 25520332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients.
    Breitkopf R; Treml B; Senoner T; Bukumirić Z; Rajsic S
    J Fungi (Basel); 2023 Feb; 9(2):. PubMed ID: 36836384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Echinocandin use in lung transplant recipients.
    Al Jishi Y; Rotstein C; Kumar D; Humar A; Singer LG; Keshavjee S; Husain S
    Clin Transplant; 2018 Dec; 32(12):e13437. PubMed ID: 30375050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
    Wang JF; Xue Y; Zhu XB; Fan H
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients.
    Kang WH; Song GW; Lee SG; Suh KS; Lee KW; Yi NJ; Joh JW; Kwon CHD; Kim JM; Choi DL; Kim JD; Kim MS
    J Gastrointest Surg; 2020 Apr; 24(4):832-840. PubMed ID: 31066013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.
    Baker AW; Maziarz EK; Arnold CJ; Johnson MD; Workman AD; Reynolds JM; Perfect JR; Alexander BD
    Clin Infect Dis; 2020 Jan; 70(1):30-39. PubMed ID: 30801642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.
    Biehl LM; Vehreschild JJ; Liss B; Franke B; Markiefka B; Persigehl T; Bücker V; Wisplinghoff H; Scheid C; Cornely OA; Vehreschild MJ
    J Antimicrob Chemother; 2016 Sep; 71(9):2634-41. PubMed ID: 27317443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal prophylaxis in liver transplant recipients: one size does not fit all.
    Giannella M; Bartoletti M; Morelli M; Cristini F; Tedeschi S; Campoli C; Tumietto F; Bertuzzo V; Ercolani G; Faenza S; Pinna AD; Lewis RE; Viale P
    Transpl Infect Dis; 2016 Aug; 18(4):538-44. PubMed ID: 27237076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients.
    Yetmar ZA; Lahr B; Brumble L; Gea Banacloche J; Steidley DE; Kushwaha S; Beam E
    Transpl Infect Dis; 2021 Oct; 23(5):e13714. PubMed ID: 34435415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
    BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.